Home › B-Cell Lymphoma › Texas › Houston
B-Cell Lymphoma clinical trials in Houston, TX
16 studies for B-Cell Lymphoma are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
- Texas Children's Hospital, Houston
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingPhase 3
- Md Anderson Cancer Center, Houston
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
RecruitingPhase 2
- MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RecruitingPhase 2
- Research Site, Houston
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 1/2
- The University of Texas Md Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
- Research Site, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
RecruitingPhase 1
- Clinical Trial Site, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RecruitingPhase 1/2
- M D Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
RecruitingPhase 1
- The University of Texas M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
RecruitingPhase 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RecruitingPhase 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
B-Cell Lymphoma trials in other cities
- New York City, NY19 studies
- Chicago, IL12 studies
- Philadelphia, PA11 studies
- Nashville, TN11 studies
- Rochester, MN10 studies
- Baldwin Park, CA9 studies
- Milwaukee, WI9 studies
- Cleveland, OH9 studies
- Salt Lake City, UT8 studies
- Boston, MA8 studies
- Pittsburgh, PA7 studies
- Charlotte, NC7 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)121 studies
- Metastatic Cancer104 studies
- Colorectal Cancer102 studies
- Ovarian Cancer89 studies
- Acute Myeloid Leukemia85 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer68 studies
- Pancreatic Cancer61 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.